electroCore, Inc. (NASDAQ: ECOR) has issued four patents related to its non-invasive vagus nerve stimulation (nVNS) and other technologies, including the following patents:
One patent, entitled “Mobile Phone for Treating a Patient with Dementia”. issued on August 9, is generally related to nVNS therapies for treating neurodegenerative diseases, such as dementia or Alzheimer’s disease with a stimulator coupled to a mobile device, such as a mobile phone;
Another, “Devices and Methods for Remote Therapy and Patient Monitoring” issued on September 6, is generally related to nVNS that includes a stimulator coupled to a mobile device, such as a mobile phone whereby the stimulator is capable of transmitting data to the mobile device. that includes, among other things, the position of the electrode(s) on the skin surface relative to the target nerve;
Still another, entitled “Electrical Nerve Stimulation to Treat Gastroparesis, Functional Dyspepsia, and Other Functional Gastrointestinal Disorders” issued on September 13. This patent is generally related to nVNS therapies for treating post-operative ileus; and
The final one, issued yesterday and entitled “Stimulator for Use with a Mobile Device” is another in the series of patents that electroCore has received which are generally related to the use of nerve stimulators with mobile devices, such as a mobile phone.
The patent includes device and method claims for generating an electrical impulse with a stimulator coupled to a mobile device and applying the electrical impulse through an outer skin surface to a target site in the patient.
ECOR shares increased a penny, or 2.2%, to 49 cents.